Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 4/2000

01-07-2000 | Adis New Drug Profile

Bexarotene

A Viewpoint by Alain H. Rook, Michael S. Lehrer, Jacqueline M. Junkins-Hopkins, Carmella C. Vittorio, Lars E. French

Authors: Alain H. Rook, Michael S. Lehrer, Jacqueline M. Junkins-Hopkins, Carmella C. Vittorio, Lars E. French

Published in: American Journal of Clinical Dermatology | Issue 4/2000

Login to get access

Excerpt

Cutaneous T cell lymphoma (CTCL) and psoriasis are chronic inflammatory disorders. The former is a malignant proliferation of skin invasive CD4+ T cells while the latter is characterized by a T cell-driven inflammatory response within the skin in association with proliferation of the epidermis. Retinoids have become important therapeutic agents in the treatment of both CTCL and psoriasis. In this regard, substantial interest has been focused on the newly released retinoid X receptor-specific retinoid, bexarotene. This compound has demonstrated a high level of clinical activity in the treatment of CTCL in phase II/III trials.[1] Furthermore, clinical benefit for psoriasis has also been observed in phase II trials.[2] …
Literature
1.
Duvic M., Martin A., Hymes K., et al. Oral bexarotene capsules as treatment for all stages of refractory or persistent CTCL [abstract no. 150]. J Invest Dermatol 2000 114: 776
2.
Smit J., de Jong E., van Hooijdonk C., et al. A multicentre phase II clinical and immunohistochemical trial of systemic bexarotene (Targretin) in psoriasis [abstract no. 151]. J Invest Dermatol 2000, 114: 776
3.
Boehm M.F., Heyman R.A., Patel S., et al. Retinoids: Biological function and use in the treatment of dermatological diseases. Expert Opin Invest Drug 1995, 4: 593–612CrossRef
4.
Fox F.E., Kubin M., Cassin M., et al. Retinoids synergize with interleukin-2 to augment interferon gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Res 1999, 19: 407–415CrossRef
Metadata
Title
Bexarotene
A Viewpoint by Alain H. Rook, Michael S. Lehrer, Jacqueline M. Junkins-Hopkins, Carmella C. Vittorio, Lars E. French
Authors
Alain H. Rook
Michael S. Lehrer
Jacqueline M. Junkins-Hopkins
Carmella C. Vittorio
Lars E. French
Publication date
01-07-2000
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 4/2000
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200001040-00007

Other articles of this Issue 4/2000

American Journal of Clinical Dermatology 4/2000 Go to the issue

Adis New Drug Profile

Bexarotene

Leading Article

The Antibacterial-Corticosteroid Combination

Leading Article

Is Acne an Infection of Blocked Pilosebaceous Follicles?

Pharmacovigilance

Drug Reaction Case Reports

Review Article

Body Dysmorphic Disorder

Adis New Drug Profile

Bexarotene